1-amino-3-hydroxy-3-methylbutan-2-one hydrochloride | 885033-77-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-amino-3-hydroxy-3-methylbutan-2-one hydrochloride
• 英文别名: 1-Amino-3-hydroxy-3-methylbutan-2-one hydrochloride；1-amino-3-hydroxy-3-methylbutan-2-one;hydrochloride
• CAS: 885033-77-2
• 化学式: C₅H₁₁NO₂*ClH
• 分子量: 153.609
• InChiKey: VUHOSELPZGOZFG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.29
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  63.3
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-amino-3-hydroxy-3-methylbutan-2-one hydrochloride 在 甲烷磺酸 、 三乙胺 、 mercury dichloride 作用下， 以 乙醇 为溶剂， 生成 tert-butyl (6S,9R)-6-(2,3-difluorophenyl)-3-(1-methoxy-1-methylethyl)-6,7,8,9-tetrahydro-5H-imidazo[1,2-a]azepin-9-ylcarbamate
  参考文献：
  名称：

  Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: Discovery of MK-2918

  摘要：

  In our ongoing efforts to develop CGRP receptor antagonists for the treatment of migraine, we aimed to improve upon telecagepant by targeting a compound with a lower projected clinical dose. Imidazoazepanes were identified as potent caprolactam replacements and SAR of the imidazole yielded the tertiary methyl ether as an optimal substituent for potency and hERG selectivity. Combination with the azabenzoxazinone spiropiperidine ultimately led to preclinical candidate 30 (MK-2918). (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.12.054
• 作为产物：
  描述：

  1--3-methyl-2-butene 在 盐酸 、 potassium permanganate 、 水 作用下， 以 甲醇 、 溶剂黄146 、 丙酮 为溶剂， 生成 1-amino-3-hydroxy-3-methylbutan-2-one hydrochloride
  参考文献：
  名称：

  Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: Discovery of MK-2918

  摘要：

  In our ongoing efforts to develop CGRP receptor antagonists for the treatment of migraine, we aimed to improve upon telecagepant by targeting a compound with a lower projected clinical dose. Imidazoazepanes were identified as potent caprolactam replacements and SAR of the imidazole yielded the tertiary methyl ether as an optimal substituent for potency and hERG selectivity. Combination with the azabenzoxazinone spiropiperidine ultimately led to preclinical candidate 30 (MK-2918). (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.12.054

文献信息

• WO2006/44504
  申请人：——

  公开号：——

  公开（公告）日：——
• CGRP RECEPTOR ANTAGONISTS
  申请人：Merck & Co., Inc.

  公开号：EP1802637A1

  公开（公告）日：2007-07-04
• [EN] CGRP RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES AUX RÉCEPTEURS DE CGRP
  申请人：MERCK & CO INC

  公开号：WO2006044504A1

  公开（公告）日：2006-04-27

  [EN] Compounds of Formula (I): and Formula (II): (where variables R[FR] La présente invention décrit des composés de Formule (I) : et de Formule (II) : (où les variables R
• Orally bioavailable imidazoazepanes as calcitonin gene-related peptide (CGRP) receptor antagonists: Discovery of MK-2918
  作者：Daniel V. Paone、Diem N. Nguyen、Anthony W. Shaw、Christopher S. Burgey、Craig M. Potteiger、James Z. Deng、Scott D. Mosser、Christopher A. Salvatore、Sean Yu、Shane Roller、Stefanie A. Kane、Harold G. Selnick、Joseph P. Vacca、Theresa M. Williams

  DOI：10.1016/j.bmcl.2010.12.054

  日期：2011.5

  In our ongoing efforts to develop CGRP receptor antagonists for the treatment of migraine, we aimed to improve upon telecagepant by targeting a compound with a lower projected clinical dose. Imidazoazepanes were identified as potent caprolactam replacements and SAR of the imidazole yielded the tertiary methyl ether as an optimal substituent for potency and hERG selectivity. Combination with the azabenzoxazinone spiropiperidine ultimately led to preclinical candidate 30 (MK-2918). (C) 2010 Elsevier Ltd. All rights reserved.